- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04571164
A Study to Evaluate the Effectiveness and Safety of LY03003 in Patients With Early Primary PD
May 5, 2023 updated by: Luye Pharma Group Ltd.
A Multi-centre,Randomized,Double-blind,Placebo Parallel Controlled Study to Evaluate the Effectiveness and Safety of LY03003 in Patients With Early Primary PD
This study is to evaluate the effictiveness and safety of Ly03003 following intramuscular injections
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
294
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Shuren Guo Guo
- Phone Number: 13501029003
- Email: guoshuren@luye.com
Study Locations
-
-
-
Beijing, China
- Xuanwu Hospital Capital Medical University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
28 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Informed consent must be given to the trial and written informed consent must be voluntarily signed, good communication with the investigator and compliance with all requirements of the clinical trial (planned visits, laboratory tests and other procedures);
- Age ≥30 years old, regardless of gender;
- The subject has had primary Parkinson's disease for less than 5 years, and the diagnosis is based on the main symptom -- motor delay plus at least 1 symptom: quiescence tremor, myotonia, and no other known or suspected cause of Parkinson's disease;
- Hoehn-yahr grading ≤3 (excluding 0);
- Brief mental state examination (MMSE) ≥25 points;
- Unified Parkinson disease rating scale (UPDRS) motor score (part Ⅲ) 10 or higher;
- If the subjects are receiving anticholinergic drugs (such as benzalkonium tropic, benzene hai suo, diethyl promethazine, its organism and than pp board), MAO - B inhibitors (e.g., company to gillan, LeiSha gillan), NMDA antagonists, such as amantadine treatment, must dose before baseline stability at least 28 days, and maintain the dose treatment during the study period
- Women of childbearing age (defined as women who have not undergone surgical sterilization or less than 1 year after menopause) or male subjects agree to use reliable contraceptives (oral contraceptives, condom use, abstinence, etc.) throughout the study period (until the end of the study), and pregnancy outcomes were negative for women of childbearing age at screening and baseline.
Exclusion Criteria:
- History of pallidotomy, thalamotomy, deep brain stimulation or fetal tissue transplantation
- Dementia, active mental illness or hallucination, major depression
- Those who received dopamine receptor agonists within 28 days before baseline
- Patients receiving levodopa preparation (including levodopa compound preparation) within 28 days before baseline, or levodopa preparation after diagnosis for more than 6 months
- Patients receiving any of the following drugs within 28 days before baseline: amphetamine, metoclopramide, α-methyldopa, antipsychotics, MAO-Ainhibitors, flunarizine, reserpine, methylphenidate, budesonide, etc
- Active central nervous system drugs (such as sedatives, hypnotics, antidepressants, and antianxiety drugs) are under treatment, except those who have maintained a stable dose for at least 28 days before the baseline (visit 2) and may remain stable during the study period
- Atypical Parkinson's disease symptoms caused by taking drugs (such as metoclopramide, flunarizine), hereditary metabolic diseases of nervous system (such as Wilson's disease), encephalitis, cerebrovascular diseases or degenerative diseases (such as progressive supranuclear paralysis)
- Have a history of epilepsy, or have a history of stroke or transient cerebral ischemia within 1 year before the visit
- Those who are intolerant or allergic to the following antiemetic drugs, such as domperidone, trimethoxybenzamide, ondansetron, tropisetron, granisetron and glinbromide
- Patients with clinically significant abnormal liver function were defined as total bilirubin > 1.5 times of the upper limit of the reference value range or ALT or ast > 2 times of the upper limit of the reference value range
- Patients with clinically significant renal dysfunction (serum creatinine > 2.0 mg / dl [> 177 μ mol / l])
- Patients with uncontrollable or important cardiovascular diseases, including congestive heart failure of NYHA grade II or above, unstable angina pectoris, myocardial infarction within 6 months before the first administration of trial drug, or arrhythmia requiring treatment at the time of screening
- At screening, QTc interval: male > 450ms, female > 460ms
- Patients with a history of orthostatic hypotension, or those with SBP ≥ 20mmhg or DBP ≥ 10mmhg at screening (visit 1) and baseline (visit 2) when switching from supine position to upright position for 1 or 3 minutes; or those with SBP < 105mmhg at visit 1 and visit 2;
- Subjects with evidence of impulse control disorder (ICD) during screening (visit 1);
- A history of suicide attempt (including actual attempt, interruption or failure of attempt) or suicidal ideation in the past 6 months were defined as those who answered "yes" to question 4 or question 5 of the Columbia suicide severity rating scale (c-ssrs) during screening (visit 1);
- Patients with history of narcolepsy;
- Those who had a history of alcoholism, drug abuse and drug abuse in the past five years (visit 1) were screened. Alcoholism was defined as drinking more than 14 units of alcohol per week (1 unit = 360 ml beer or 45 ml alcohol with 40% alcohol content or 150 ml wine);
- Patients with malignant tumor within 5 years before screening were excluded from cervical carcinoma in situ, skin basal cell or squamous cell carcinoma, local prostate cancer after radical operation and breast intraductal carcinoma in situ after radical operation;
- Pregnant or lactating women;
- The patients who had participated in the rotigotine test were intolerable or ineffective;
- Allergic constitution (allergic to two or more drugs or foods) or known to be allergic to rotigotine or rotigotine microspheres;
- Those who have participated in clinical trials of other drugs within 3 months before screening;
- Other clinically significant medical status, mental status or laboratory abnormalities judged by the researcher may interfere with the subject's ability to participate in the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
During the intervention,the initial does was 14mg,and then was incremented in weekly units,14mg each time,until the maximum does of 56mg set in this study was reached 4 weeks after titration,the optimal therapeutic does or the maximum tolerated does was entered into the dosing maintenance period.After entering the maintenance period,no does adjustment was performed,and the stable does was maintained for 24 weeks.
|
Experimental: LY03003
|
During the intervention, the initial dose was 14mg, and then was incremented in weekly units, 14mg each time, until the maximum dose of 56mg set in this study was reached 4 weeks after titration, the optimal therapeutic dose or the maximum tolerated dose was entered into the dosing maintenance period.
After entering the maintenance period, no dose adjustment was performed, and the stable dose was maintained for 24 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline to the end of the treatment period in the Unified Parkinson's Disease Rating Scale(UPDRS)part(Ⅱ+Ⅲ)Total Score
Time Frame: From baseline to the end of the double-blind dose maintenance period at 24weeks
|
From baseline to the end of the double-blind dose maintenance period at 24weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The proportion of patients whose total UPDRS decreased by 20、25、30percent or mors
Time Frame: From baseline to the end of the double-blind dose maintenance period at 24weeks
|
From baseline to the end of the double-blind dose maintenance period at 24weeks
|
UPDRS scale part Ⅱchanges relative to the baseline
Time Frame: From baseline to the end of the double-blind dose maintenance period at 24weeks
|
From baseline to the end of the double-blind dose maintenance period at 24weeks
|
UPDRS scale part Ⅲchanges relative to the baseline
Time Frame: From baseline to the end of the double-blind dose maintenance period at 24weeks
|
From baseline to the end of the double-blind dose maintenance period at 24weeks
|
Changes in SI scores in the Total Clinical Efficacy Rating Scale (CGI) relative to baseline,the scores of GI and EI
Time Frame: From baseline to the end of the double-blind dose maintenance period at 24weeks
|
From baseline to the end of the double-blind dose maintenance period at 24weeks
|
To clarify the changes in PDQ-8 questionnaire scores relative to baseline
Time Frame: From baseline to the end of the double-blind dose maintenance period at 24weeks
|
From baseline to the end of the double-blind dose maintenance period at 24weeks
|
To clarify the changes in PDSS questionnaire scores relative to baseline
Time Frame: From baseline to the end of the double-blind dose maintenance period at 24weeks
|
From baseline to the end of the double-blind dose maintenance period at 24weeks
|
To clarify the changes in BDI-Ⅱquestionnaire scores relative to baseline
Time Frame: From baseline to the end of the double-blind dose maintenance period at 24weeks
|
From baseline to the end of the double-blind dose maintenance period at 24weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 11, 2020
Primary Completion (Actual)
March 17, 2022
Study Completion (Actual)
September 27, 2022
Study Registration Dates
First Submitted
September 21, 2020
First Submitted That Met QC Criteria
September 25, 2020
First Posted (Actual)
September 30, 2020
Study Record Updates
Last Update Posted (Estimate)
May 8, 2023
Last Update Submitted That Met QC Criteria
May 5, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Parkinsonian Disorders
- Basal Ganglia Diseases
- Movement Disorders
- Synucleinopathies
- Neurodegenerative Diseases
- Parkinson Disease
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Dopamine Agonists
- Dopamine Agents
- Rotigotine
Other Study ID Numbers
- LY03003/CT-CHN-304
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
ProgenaBiomeRecruitingParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
-
King's College LondonGlaxoSmithKlineCompletedParkinson Disease | Idiopathic Parkinson Disease | Parkinson Disease, PARK8United Kingdom
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
National Yang Ming UniversityUnknownEarly Onset Parkinson Disease | Early Stage Parkinson Disease
-
Michele Tagliati, MDRecruitingREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Cedars-Sinai Medical CenterEnrolling by invitationREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Mahatma Gandhi Institute of Medical SciencesCompletedStroke, Parkinson' s Disease, Neurological Impairments, Tele-rehabilitationIndia
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
University of DeustoCompletedPARKINSON DISEASE (Disorder)Spain
Clinical Trials on LY03003(Rotigotine,extended-release microspheres)
-
Luye Pharma Group Ltd.Beijing Bozhiyin T&S Co., Ltd.CompletedParkinson DiseaseChina
-
Luye Pharma Group Ltd.Beijing Bozhiyin T&S Co., Ltd.CompletedParkinson Disease
-
Luye Pharma Group Ltd.Completed
-
Luye Pharma Group Ltd.CompletedParkinson DiseaseUnited States
-
Peking University Third HospitalCompleted
-
Hangzhou Highlightll Pharmaceutical Co., LtdCompleted
-
Luye Pharma Group Ltd.Shandong Luye Pharmaceutical Co., Ltd.Completed
-
AstraZenecaWithdrawnHealthy Male Subjects | Pharmacokinetics | Safety | Food EffectUnited Kingdom
-
Luye Pharma Group Ltd.CompletedParkinson's DiseaseUnited States
-
Ultragenyx Pharmaceutical IncCompletedHereditary Inclusion Body Myopathy (HIBM)United States